



Canada's source for
HIV and hepatitis C
information

La source canadienne
de renseignements sur
le VIH et l'hépatite C



CanHepC

Canadian Network on Hepatitis C
Réseau Canadien sur l'Hépatite C

Delivering a Cure for Hepatitis C Infection: What Are the Remaining Gaps? An Overview of the Latest in Research and Implications for Frontline Efforts

March 15th 2017

Suzanne Fish

Knowledge Broker, Hepatitis C Community Health Programming,
CATIE

www.catie.ca

Overview



1. Context of the 6th Canadian HCV Symposium
2. CATIE Learning Institute
3. Key research from the Symposium
4. Community/ Research discussion

Sandrine Brodeur, AQPSUD

Mohamed, CanHep C Postdoctoral Fellow

5. Questions

Context



- Canada's premier Hepatitis C research conference
- Important annual event to disseminate new HCV research
- 6th year
- Title: "Delivering a Cure for Hepatitis C Infection: What are the remaining Gaps?"
- 250 participants



CATIE Learning Institute



Knowledge Exchange event

Goals:

- Synthesize and disseminate research across regions
- Bring community realities into Symposium
- Networking

10 Representatives from across Canada



This presentation is a product of our collective synthesis:

- Most relevant research for front line organizations
- Community perspective

Key Research



Delivering a cure for Hepatitis C Infection: What are the remaining gaps?

Remaining gaps?

Depends on the goal:

- Developing curative HCV treatments?
- Elimination of HCV?
- Something broader (Social determinants of health, liver health, etc.)

Definitions

- *Eradication*: Permanent reduction to zero of worldwide incidence
- *Elimination*: Reduction to zero of incidence in a defined geographic area

Slide 5

LM3

eliminate liver DAMAGE (not failure, I think).

Liam Michaud, 3/3/2016

Treatments: Remaining Gaps?

Curative treatments – Remaining gaps?

- Difficult to cure:
 - Genotype 3 with cirrhosis
 - Advanced liver disease
 - Treatment resistance

Genotype 3

- New pan genotypic regimes have very high cure rates above 95% (Pawlotsky)
- SOF/VEL/VOX : Cure rates greater than 95%
- Glecaprevir/Pibrentasvir: Cure rates greater than 96%



Treatments: Remaining Gaps?

Advanced Liver disease (Pawlotsky, J.)

- SOF/LED + Rbv – good cure rates, near 90%
- Only 17-33% improvement in liver disease after cure
- Therefore a) treat earlier b) liver transplant then treat

Resistance to DAA treatments (Pawlotsky, J.)

- Next generation regimes very promising with cure rates 95% and higher.
 - Glecaprevir + Pibrentasvir: cure rates near 98%
 - Grazoprevir/Elbasvir + Rbv: cure rates of 100% for genotype 1
 - SOF/VEL/VOX: Above 95% for all genotypes
-
- Curative treatments exist for vast majority. Remaining gaps mostly for those with advanced liver disease, but new generation will close that gap significantly.

Elimination: Remaining Gaps?



Elimination: Remaining Gaps ?

- Access to treatment (F2 and physicians)
- Testing
- Access to programming
- Prevention

Access to treatment

- To achieve elimination by 2030, need universal access (Sherman, M. and Myers, R.)
- Progressive approach of several provinces is promising: eligibility
- Access to treatment in prisons
- Adherence amongst PWID is high – 94% in Community Based Toronto Program (Guyton, et. Al)
- Intellectual scotoma, profiling (Lafontaine, A.)
- Broaden prescriber base for those with low fibrosis - beyond gastro/ID- (Grebely, J. Kirby Institute)

Elimination: Remaining Gaps?



Testing and linkage to care

- Testing remains sub optimal
- Must develop strategies to screen priority populations: baby boomers, immigrants/newcomers, people in prison, Indigenous peoples, people who use injections drugs (Sherman, M.)
- Xpert HCV RNA testing good sensitivity and specificity (Grebely, J. Kirby Institute)

Elimination: Remaining Gaps?



Access to programming

- Progressive access to treatment but access to programming remains a major gap (Krajden, M.)
- BC Hepatitis Testers cohort - comprehensive surveillance program: Individuals with mental health and cirrhosis not getting on treatment
- Solutions exist: Hepatitis C Treatment and Care in Big River First Nation Community (Pandey, M.)

Barriers: Transportation, information on navigating the system, racism, confidentiality.

Solutions: Local health care centre, nurse-led model, use of technology, federally funded nursing staff, elder and community support, mobile clinic.

- Provincial / national strategies (Barrett, L.)

Elimination: Remaining Gaps?



Access to prevention programming

- Prevention of primary infection and re-infection must be improved to reduce burden of disease (Hagan, H. New York University)
- Enhanced harm reduction reduces the risk of HCV infection by more than 70%. This includes:
 - a) OST
 - b) High syringe coverage – no limit to needles
 - c) Access to cookers, cottons and other equipment (20 –60% of infections)
 - d) Safe drug use education
 - e) Safe consumption sites
 - e) Treatment and prevention networks (social support, wake up dose, periodic detox to lower tolerance, etc.)
- Minority of PWID have access to these programs

Elimination: Remaining Gaps?



Access to prevention programming

- 1 in 10 people with addictions receive any kind of treatment (Wood, E.)
- Totally new approach needed: e.g primary care based model of addiction services
- Yet even adequately funding existing addiction services would have significant impact (Wood, E.)

Broader Goals: Remaining Gaps?



Broader Goals

- Liver cancer/ fibrosis
- Social determinants of health
- Broad personal and social transformation: Indigenous approach to wellness/change

Liver cancer/Fibrosis

- Liver cancer second leading cause of cancer death in the world
- Following viral cure, risk of liver cancer decreases but remains significant
- Strategies to prevent liver disease progression and cancer
- Instead of targeting viral proteins, modulate virus-host interactions

Broader Goals: Remaining Gaps?



Social determinants of health

- Social drivers of HCV and other health issues: public health response (Tyndall, M.)
- Populations most affected dealing with overdose, homelessness, food insecurity, etc.
- Broaden what we measure
- Legalization of drugs will have significant impact on social drivers of the problem (Woods, E.)

Broader Goals: Remaining Gaps?



Indigenous approach to wellness/change

- Wholistic Hepatitis C care is about broad personal/social change, not simply eliminating virus (King, A.)
- 4 laws of change (Lund, C):
 - 1) Change is from within
 - 2) Must be preceded with a vision
 - 3) Great learning must occur
 - 4) Requires a healing environment
- Harmonize traditional and western models of wellness
- Connection to earth, ceremonies, relationships
- Research in a good way: Acknowledge history, decolonize relations, community based research which transforms through the process (Masching, R.)

Conclusions



Remaining Gaps?

- Depends on goal and location—crack and chasm
- Highly effective curative treatments developed
- Elimination may be possible by 2030 but requires access to treatment, programming and broad testing
- Broad social transformation, decolonization, healing is an ongoing process
- In choosing our models, explore the goals/outcomes carefully: Australian model, Indigenous community based models, other models of care.

Community/Research Discussion




Learning from the frontline and community

Knowledge Exchange events

Goals:

- Bridging the gap between researchers & community
- Creating mutual perspectives & agendas
- Prioritizing what community needs
- **Minimizing sensitivity in collaboration**



"I'm right there in the room, and no one even acknowledges me."

Thank you



Learning Institute Participants

Julie Beaulieu – Centre SIDA Amitie

Barb Bowditch – Access Place

Sandrine Brodeur – AQPSUD

Angelina Butt – Aids Committee of Newfoundland and Labrador

Lauren Charles – Access Place

Eric Dang – Streetworks

Zoe Dodd – Toronto Hepatitis C Program

Lindsay Jennings – PASAN

Sandy-Leo Laframboise – Dancing Eagle Spirit

Anu Randhawa – Punjabi Community Health Services

CATIE Staff

Scott Anderson

Melisa Dickie

Liam Michaud

Fozia Tanveer

Thank you



CanHep C Trainees

Mohamed Abdel-Hakeem, Post Doctoral Fellow – University of Pennsylvania

Annie Bernier, PhD Candidate – McGill University

Thomas Fabre, PhD Candidate - University of Montreal

Emmanuel Fortier, MD/PhD – University of Montreal

Sahar Saeed, PhD Candidate – McGill University

www.catie.ca

Questions

Please evaluate this webinar.

Thank you!

